Stock has been on a major run up 90% + for the year..Potential exists for further gains associated with bird flu scares, also any positive results from health canada due out next week regarding companies new insulin spray..
GNBT
- Thread starter Purple_Reign
- Start date
GNBT GENEREX BIOTECHNOLOGY CORPORATION
Trade Research Add to Watch List Detailed Quote Option Chain
Last [Tick] 2.29[ + ]
Change 0.42
% Change 22.46%
Bid 2.29
Bid Size 7
Ask 2.29
Ask Size 85
Open 1.90
Volume 12,268,673
Day High 2.34
Day Low 1.88
Previous Close 1.87
Prev. Close Date 02/23/2006
Restricted Indicator R
Trade Research Add to Watch List Detailed Quote Option Chain
Last [Tick] 2.29[ + ]
Change 0.42
% Change 22.46%
Bid 2.29
Bid Size 7
Ask 2.29
Ask Size 85
Open 1.90
Volume 12,268,673
Day High 2.34
Day Low 1.88
Previous Close 1.87
Prev. Close Date 02/23/2006
Restricted Indicator R
P R
What do you expect from this stock? I will sell some of mine as it is up before opening and I have a nice profit.
Thanks for this great tip!!
MSM
What do you expect from this stock? I will sell some of mine as it is up before opening and I have a nice profit.
Thanks for this great tip!!
MSM
MSM,
not sure is the honest answer... There are many reasons to like the stock..Bird flu scare-possible govt contract on vaccine? ,Oral Lyn insulin spray which may replace needles for diabetics eventually, selling in equador now more countries likely approve it soon..If the consumer buys it would be a huge earnings source..But the reality is they have little earnings as of now only things in the pipeline so it is highly speculative...This is my strategy with this stock, I try to follow the rule of don't sell when a stock is making a new 52wk high which for this one is every day and don't be afraid to buy more if a stock breaks out..I've been accumulating this stock since my entry point at 1.30 per share and may buy more..So I am long and strong but highly tempered if i notice two days of heavy correction say 20% or so on "heavy" volume than i will start selling off..Also try to follow the rule never let a sure profit turn into a loss..hope that helps..Glad this stock is doing so well wanted to pick one to give something back...Happy speculating and good luck.
not sure is the honest answer... There are many reasons to like the stock..Bird flu scare-possible govt contract on vaccine? ,Oral Lyn insulin spray which may replace needles for diabetics eventually, selling in equador now more countries likely approve it soon..If the consumer buys it would be a huge earnings source..But the reality is they have little earnings as of now only things in the pipeline so it is highly speculative...This is my strategy with this stock, I try to follow the rule of don't sell when a stock is making a new 52wk high which for this one is every day and don't be afraid to buy more if a stock breaks out..I've been accumulating this stock since my entry point at 1.30 per share and may buy more..So I am long and strong but highly tempered if i notice two days of heavy correction say 20% or so on "heavy" volume than i will start selling off..Also try to follow the rule never let a sure profit turn into a loss..hope that helps..Glad this stock is doing so well wanted to pick one to give something back...Happy speculating and good luck.
on the move again
Last Price Day Change Volume
$4.87 0.64 (15.13%) 35,747,068
Open Price Day Range 52-Wk Range
$4.39 5.02 - 4.27 4.49 - 0.51
Mkt Cap($mil) Yield Avg Volume
228 0.00% 12,409,567
P/E P/S P/CF
NA NA NA
Last Price Day Change Volume
$4.87 0.64 (15.13%) 35,747,068
Open Price Day Range 52-Wk Range
$4.39 5.02 - 4.27 4.49 - 0.51
Mkt Cap($mil) Yield Avg Volume
228 0.00% 12,409,567
P/E P/S P/CF
NA NA NA
PULSE: Generex reports positive results for oral insulin product
03-15-06 02:13 PM EST
BOSTON (MarketWatch) -- Generex (GNBT) said Wednesday that preliminary study results show its orally-administered insulin product, Oral-lyn, was effective in controlling blood sugar levels in adolescents and young adults with type 1 diabetes. The results are from data collected during the first ten weeks of a six-month long clinical trial. As opposed to traditional insulin, which is injected, Oral-lyn is administered into the mouth via a spray. Although the product is on the market in Ecuador, Oral-lyn has not yet been given U.S. regulatory approval. Generex shares were up almost 7% at $2.26 in afternoon trade.
03-15-06 02:13 PM EST
BOSTON (MarketWatch) -- Generex (GNBT) said Wednesday that preliminary study results show its orally-administered insulin product, Oral-lyn, was effective in controlling blood sugar levels in adolescents and young adults with type 1 diabetes. The results are from data collected during the first ten weeks of a six-month long clinical trial. As opposed to traditional insulin, which is injected, Oral-lyn is administered into the mouth via a spray. Although the product is on the market in Ecuador, Oral-lyn has not yet been given U.S. regulatory approval. Generex shares were up almost 7% at $2.26 in afternoon trade.
down HUGE right now. any idea?
this looks like total manipulation. almost tempted to buy on this dip but it's not just an avg dip, something's wrong. I'm afraid if I bought before market close, it'll drop another 10-15% afterhours.
this looks like total manipulation. almost tempted to buy on this dip but it's not just an avg dip, something's wrong. I'm afraid if I bought before market close, it'll drop another 10-15% afterhours.
Generex Biotechnology Subsidiary Receives Patent From European Patent Office
05-01-06 07:30 AM EST --(MARKET WIRE)--
TORONTO -- (MARKET WIRE) -- 05/01/06 -- Generex Biotechnology Corporation (NASDAQ: GNBT) announced today that its wholly owned subsidiary, Antigen Express, Inc., has been granted a European patent titled "Regulation of Antigen Presentation." The patent issued on December 21, 2005 relates to the use of Ii-Key peptides in regulating antigen presentation. It broadly covers the use of Ii-Key in potential immunotherapy treatments of cancer and infectious diseases.
Antigen Express is pursuing novel immunotherapeutics based on the antigen-specific stimulation of T helper cells. The use of Ii-Key to augment the potency of antigenic peptides constitutes one of two platform technologies being developed at the Company. The most advanced of these projects employs an Ii-Key modified peptide from the tumor-associated HER-2/neu protein. That compound has been in the clinic for a year in patients with breast cancer and has shown good activity in stimulating T helper cells to specifically recognize HER-2/neu. A similar vaccine employing Ii-Key and a fragment of the H5 protein from the H5N1 virus is being developed as a prophylactic vaccine for the potentially pandemic H5N1 avian influenza virus.
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.
For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
05-01-06 07:30 AM EST --(MARKET WIRE)--
TORONTO -- (MARKET WIRE) -- 05/01/06 -- Generex Biotechnology Corporation (NASDAQ: GNBT) announced today that its wholly owned subsidiary, Antigen Express, Inc., has been granted a European patent titled "Regulation of Antigen Presentation." The patent issued on December 21, 2005 relates to the use of Ii-Key peptides in regulating antigen presentation. It broadly covers the use of Ii-Key in potential immunotherapy treatments of cancer and infectious diseases.
Antigen Express is pursuing novel immunotherapeutics based on the antigen-specific stimulation of T helper cells. The use of Ii-Key to augment the potency of antigenic peptides constitutes one of two platform technologies being developed at the Company. The most advanced of these projects employs an Ii-Key modified peptide from the tumor-associated HER-2/neu protein. That compound has been in the clinic for a year in patients with breast cancer and has shown good activity in stimulating T helper cells to specifically recognize HER-2/neu. A similar vaccine employing Ii-Key and a fragment of the H5 protein from the H5N1 virus is being developed as a prophylactic vaccine for the potentially pandemic H5N1 avian influenza virus.
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.
For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
Clinician Presents Generex Oral-lyn(TM) Clinical Data at the Pediatric Academic Societies' 2006 Annual Meeting
05-02-06 08:00 AM EST --(MARKET WIRE)--
TORONTO -- (MARKET WIRE) -- 05/02/06 -- Generex Biotechnology Corporation (NASDAQ: GNBT), a leader in the area of buccal drug delivery, announced today that Dr. Jaime Guevara-Aguirre, M.D., of the Institute of Endocrinology IEMYR in Quito, Ecuador, was invited to make a late-breaker platform presentation of Generex Oral-lyn(TM) clinical data on May 1, 2006 at the Pediatric Academic Societies' 2006 Annual Meeting in San Francisco.
Dr. Guevara's presentation was entitled "Preliminary Results from a 6-Month Study on the Safety and Efficacy of an Oral Insulin (Generex Oral-lyn(TM)) Administered at Lunch Time in Adolescent and Young Adult Type-1 Diabetes Mellitus Subjects Maintained on Basal Subcutaneous Glargine Insulin and Pre-Breakfast and Pre-Dinner Subcutaneous Regular Insulin."
"We are most gratified that the scientific community has recognized the importance of this study and the significance of these preliminary results and invited the principal investigator to make a podium presentation of the clinical data at this important scientific symposium," said Anna Gluskin, President & Chief Executive Officer of Generex.
Participating subjects in this 6-month study are 24 adolescents (12M; 12F) and five young adults (2M; 3F) referred to the Institute of Endocrinology IEMYR in various degrees of metabolic control as reflected by altered baseline measurements of glucose 236.6 (116.6) mg/dL; fructosamine 472.6 (126.6) umol/L; and glycosylated hemoglobin (HbA1c) 9.8 (2.3) g/dL. Baseline demographics of the 24 adolescents are: Age 14.7y (2.1); Bone age 14.1 (2.2); CA/BA 1.0 (0.1); Height 153.8cm (9.4); Weight 51.0kg (10.2); BMI 21.7 (3.2); Duration of DM 6.7 (2.8). Baseline demographics of the 5 young adults are: Age 20.6y (2.2); Bone age (BA) 18.8 (0.4); CA/BA 1.1 (0.1); Height 161.1cm (12.8); Weight 62.5kg (9.3); BMI 23.0 (1.8); Duration of DM 7.0 (1.7). Mean age for the entire group is 15.7y (3.0); BA 14.9 (2.7); CA/BA 1.1 (0.1); Duration of the DM is 6.8 (2.6).
After stabilization with basal subcutaneous glargine insulin and three pre-prandial subcutaneous regular insulin injections, standard therapy continued for four weeks for comparison. Immediately thereafter, split doses of Generex Oral-lyn immediately before and after lunch replaced lunch time injections of regular insulin. Patient-collected glucose values, fructosamine, and HbA1c were compared weekly (3-4 weeks per each treatment). Values are reported at the end of each phase.
FRUCTOSAMINE HbA1C GLUCOSE (BASAL)
PHASE MEAN SD MEAN SD MEAN SD
BASELINE 476.89 130.22 9.9 2.38 236.6* 116.5
REGULAR
INSULIN 368.2 91 8.4 1.6 140.4 35.5
ORAL-LYN 379.1 133 8.5 2.1 143.3 39.9
COMPARED
TO BASELINE < .0001 < .0001 < .0005
10-WEEK DATA 377.9 98 7.9 1.6
(*Glucose values at baseline were determined by laboratory; other glucose values were determined by glucometer)
After comparison, a 6-month study of Generex Oral-lyn treatment at lunchtime was initiated. Fructosamine and HbA1c results between the 8th and 10th week of treatment demonstrated that fructosamine and HbA1c levels maintain the trend towards normalization.
In summary, successful replacement of regular subcutaneous insulin with Generex Oral-lyn during the initial 10 weeks of this 6-month trial was achieved as demonstrated by patient-collected glucose levels, fructosamine, and HbA1c measurements.
In addition to the podium presentation, Dr. Guevara made a poster presentation at the symposium of a study entitled "A 12-Day Comparison of Preprandial Humulin-R? vs. Generex Oral-lyn(TM) in 10 Type-1 Diabetic Subjects Receiving Baseline Glargine Insulin Therapy."
The aim of this pilot study was to determine the suitability of dose and formulation of Generex Oral-lyn for its use in a larger multi-center trial. The study also compared the glucodynamics of both rapid insulins (Generex Oral-lyn and Humulin-R?) in 10 Type-1 diabetic subjects receiving glargine insulin as their baseline therapy. Fructosamine, a parameter of protein glycation, was determined as part of a panel of safety monitoring.
10 Type-1 Diabetes Mellitus (DM) research subjects received their usual baseline glargine insulin (Lantus?) therapy twice daily (BID: 2/3rd in the morning and 1/3rd in the evening). Depending on present glycemia, Humulin-R was dosed as a pre-meal subcutaneous injection during days -3, -2 and -1. Five to eight puffs of Generex Oral-lyn were given pre- and post-prandially on days +1 through +9. Adjustments of glycemia were done using standard snacks, additional subcutaneous Humulin-R or Generex Oral-lyn puffs.
Peripheral glucose measurements were self-monitored by the 10 DM Type-1 research subjects in duplicate at each time-point by using a common standard method (Accu-Chek?). The peripheral glucose concentration average of the 2-value performed at each time-point for the 9-day Generex Oral-Lyn (O), and 3-day Humulin-R (H) are hereby provided: Pre-Breakfast (B): 70.26 (O) vs. 91.08 (H); 1-hour (h) post-B: 138.50 (O) vs. 151.45 (H) ; 2-h post-B: 113.92 (O) vs. 108.18 (H); Pre-Lunch (L): 84.82 (O) vs. 98.55 (H); 1-post-L: 142.00 (O) vs. 140.77 (H); 2-h post-L: 113.55 (O) vs. 106.28 (H); Pre-Dinner (D): 92.84 (O) vs. 100.78 (H); 1-post-D: 141.31 (O) vs. 139.43 (H); 2-h post-D: 119.62 (O) vs. 109.94 (H). The corresponding Area Under the Curve for both treatments were compared and no statistical significance was found (p = 0.6875).
Using BID glargine insulin (Lantus) as baseline therapy, Humulin-R and Generex Oral-lyn induced similar glucodynamic responses during the 12-day observation period. Intensive monitoring and timely corrections with additional snacks, Humulin-R or Generex Oral-lyn resulted in an appropriate glycemic control as assessed by individual daily-glycemic curves and, especially, normal preprandial glycemia. Measurements of protein glycosylation displayed a tendency to lower values after the 12-day study period.
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world.
For more information, visit the Generex Web site at www.generex.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
05-02-06 08:00 AM EST --(MARKET WIRE)--
TORONTO -- (MARKET WIRE) -- 05/02/06 -- Generex Biotechnology Corporation (NASDAQ: GNBT), a leader in the area of buccal drug delivery, announced today that Dr. Jaime Guevara-Aguirre, M.D., of the Institute of Endocrinology IEMYR in Quito, Ecuador, was invited to make a late-breaker platform presentation of Generex Oral-lyn(TM) clinical data on May 1, 2006 at the Pediatric Academic Societies' 2006 Annual Meeting in San Francisco.
Dr. Guevara's presentation was entitled "Preliminary Results from a 6-Month Study on the Safety and Efficacy of an Oral Insulin (Generex Oral-lyn(TM)) Administered at Lunch Time in Adolescent and Young Adult Type-1 Diabetes Mellitus Subjects Maintained on Basal Subcutaneous Glargine Insulin and Pre-Breakfast and Pre-Dinner Subcutaneous Regular Insulin."
"We are most gratified that the scientific community has recognized the importance of this study and the significance of these preliminary results and invited the principal investigator to make a podium presentation of the clinical data at this important scientific symposium," said Anna Gluskin, President & Chief Executive Officer of Generex.
Participating subjects in this 6-month study are 24 adolescents (12M; 12F) and five young adults (2M; 3F) referred to the Institute of Endocrinology IEMYR in various degrees of metabolic control as reflected by altered baseline measurements of glucose 236.6 (116.6) mg/dL; fructosamine 472.6 (126.6) umol/L; and glycosylated hemoglobin (HbA1c) 9.8 (2.3) g/dL. Baseline demographics of the 24 adolescents are: Age 14.7y (2.1); Bone age 14.1 (2.2); CA/BA 1.0 (0.1); Height 153.8cm (9.4); Weight 51.0kg (10.2); BMI 21.7 (3.2); Duration of DM 6.7 (2.8). Baseline demographics of the 5 young adults are: Age 20.6y (2.2); Bone age (BA) 18.8 (0.4); CA/BA 1.1 (0.1); Height 161.1cm (12.8); Weight 62.5kg (9.3); BMI 23.0 (1.8); Duration of DM 7.0 (1.7). Mean age for the entire group is 15.7y (3.0); BA 14.9 (2.7); CA/BA 1.1 (0.1); Duration of the DM is 6.8 (2.6).
After stabilization with basal subcutaneous glargine insulin and three pre-prandial subcutaneous regular insulin injections, standard therapy continued for four weeks for comparison. Immediately thereafter, split doses of Generex Oral-lyn immediately before and after lunch replaced lunch time injections of regular insulin. Patient-collected glucose values, fructosamine, and HbA1c were compared weekly (3-4 weeks per each treatment). Values are reported at the end of each phase.
FRUCTOSAMINE HbA1C GLUCOSE (BASAL)
PHASE MEAN SD MEAN SD MEAN SD
BASELINE 476.89 130.22 9.9 2.38 236.6* 116.5
REGULAR
INSULIN 368.2 91 8.4 1.6 140.4 35.5
ORAL-LYN 379.1 133 8.5 2.1 143.3 39.9
COMPARED
TO BASELINE < .0001 < .0001 < .0005
10-WEEK DATA 377.9 98 7.9 1.6
(*Glucose values at baseline were determined by laboratory; other glucose values were determined by glucometer)
After comparison, a 6-month study of Generex Oral-lyn treatment at lunchtime was initiated. Fructosamine and HbA1c results between the 8th and 10th week of treatment demonstrated that fructosamine and HbA1c levels maintain the trend towards normalization.
In summary, successful replacement of regular subcutaneous insulin with Generex Oral-lyn during the initial 10 weeks of this 6-month trial was achieved as demonstrated by patient-collected glucose levels, fructosamine, and HbA1c measurements.
In addition to the podium presentation, Dr. Guevara made a poster presentation at the symposium of a study entitled "A 12-Day Comparison of Preprandial Humulin-R? vs. Generex Oral-lyn(TM) in 10 Type-1 Diabetic Subjects Receiving Baseline Glargine Insulin Therapy."
The aim of this pilot study was to determine the suitability of dose and formulation of Generex Oral-lyn for its use in a larger multi-center trial. The study also compared the glucodynamics of both rapid insulins (Generex Oral-lyn and Humulin-R?) in 10 Type-1 diabetic subjects receiving glargine insulin as their baseline therapy. Fructosamine, a parameter of protein glycation, was determined as part of a panel of safety monitoring.
10 Type-1 Diabetes Mellitus (DM) research subjects received their usual baseline glargine insulin (Lantus?) therapy twice daily (BID: 2/3rd in the morning and 1/3rd in the evening). Depending on present glycemia, Humulin-R was dosed as a pre-meal subcutaneous injection during days -3, -2 and -1. Five to eight puffs of Generex Oral-lyn were given pre- and post-prandially on days +1 through +9. Adjustments of glycemia were done using standard snacks, additional subcutaneous Humulin-R or Generex Oral-lyn puffs.
Peripheral glucose measurements were self-monitored by the 10 DM Type-1 research subjects in duplicate at each time-point by using a common standard method (Accu-Chek?). The peripheral glucose concentration average of the 2-value performed at each time-point for the 9-day Generex Oral-Lyn (O), and 3-day Humulin-R (H) are hereby provided: Pre-Breakfast (B): 70.26 (O) vs. 91.08 (H); 1-hour (h) post-B: 138.50 (O) vs. 151.45 (H) ; 2-h post-B: 113.92 (O) vs. 108.18 (H); Pre-Lunch (L): 84.82 (O) vs. 98.55 (H); 1-post-L: 142.00 (O) vs. 140.77 (H); 2-h post-L: 113.55 (O) vs. 106.28 (H); Pre-Dinner (D): 92.84 (O) vs. 100.78 (H); 1-post-D: 141.31 (O) vs. 139.43 (H); 2-h post-D: 119.62 (O) vs. 109.94 (H). The corresponding Area Under the Curve for both treatments were compared and no statistical significance was found (p = 0.6875).
Using BID glargine insulin (Lantus) as baseline therapy, Humulin-R and Generex Oral-lyn induced similar glucodynamic responses during the 12-day observation period. Intensive monitoring and timely corrections with additional snacks, Humulin-R or Generex Oral-lyn resulted in an appropriate glycemic control as assessed by individual daily-glycemic curves and, especially, normal preprandial glycemia. Measurements of protein glycosylation displayed a tendency to lower values after the 12-day study period.
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world.
For more information, visit the Generex Web site at www.generex.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
Alot of good news with this company lately...Purple Reign any kind of revised price target??...as this one is hovering aroung $3 a share
